BioCentury
ARTICLE | Company News

Caprion, Expergen GmbH deal

March 20, 2006 8:00 AM UTC

Caprion in-licensed CAP-232 ( TT-232) from technology transfer company Expergen for an undisclosed amount of stock and cash. The heptapeptide, which targets pyruvate kinase M2 isozyme (PKM2), has co...